Gilead Science Inc, announced its largest commitment to health equity for Indigenous Australian and Canadian communities. This initiative will support programs to remove social barriers to care that continue to contribute to HIV and viral hepatitis transmission in Indigenous communities. Gilead is in talks with two Indigenous-led organizations, the Lowitja […]
Featured News
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Genmab A/S today announced that the European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP) has adopted a positive opinion proposing a conditional marketing authorization for ecoritamab as monotherapy in the treatment of adult patients with relapsed or refractory dual- or multiple-lineage systemic B-cell lymphoma (DLBCL). The European Commission’s […]
Establishment Labs Celebrates Opening of Sulàyöm Innovation Campus and Outlines New and Expanded Capabilities
Establishment Labs Holdings Inc., a global health technology company dedicated to improving women’s health and well-being, primarily in breast aesthetics and reconstruction, today announced the opening of its facility at Sulayöm innovation in the Coyol Free Zone, Costa Rica. The Sulayöm campus will support the continued growth of Established Laboratories […]
Nutex health hospitals win six new outstanding awards
Nutex Health Inc., a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that six Nutex hospitals have won notable awards this quarter. Each award was voted on by their respective communities, as a reflection of […]
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
Genentech, a member of the Roche Group , announced that the OCARINA II phase III trial evaluating Ocrevus® (ocrelizumab) as a 10-minute subcutaneous injection twice a year met the primary and secondary endpoints in patients with the Relapsing MS or primary progressive MS (RMS or PPMS). Subcutaneous Ocrevus was found […]
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Incyte announced the positive review results from the pivotal study TRuE-AD3, randomized, vehicle-controlled, evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children ( ages 2 to < 12 years old) with atopic dermatitis. The study met the primary endpoint and showed more patients treated with ruxolitinib cream 0.75% […]
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
Sensorion, a pioneering clinical-stage biotech company dedicated to the development of new therapies to restore, treat, and prevent hearing loss disorders, today announced that it has submitted an Application Initial clinical trial (CTA) for OTOF-GT for the UK Medicines and Health Agency. The Healthcare Products Regulatory Authority (MHRA). The Phase […]
Bright Health Group Enters into Definitive Agreement with Molina Healthcare to Sell its California Medicare Advantage Business, Bolstering Capital Position to Continue Advancing its Value-Driven Care Model
Bright Health Group, Inc., the value-driven, technology-driven healthcare company, today announced that it has entered into a definitive agreement with Molina Healthcare, Inc. (“Molina”), for the sale of California Medicare Advantage, Brand New Day and the Central Health Plan business, for a total purchase price of $600 million. At the […]
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS, for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb announces that the European Commission has approved CAMZYOS® for the treatment of symptomatic hypertrophic obstructive cardiomyopathy in adult patients. CAMZYOS is the first and only reversible and allotropic Selective Cardiac Myosin Inhibitor approved in all Member States of the European Union* and the first Cardiac Myosin Inhibitor […]
VBA Announces Partnership With MPX to Provide Healthcare Payers With an Integrated Solution for Communications Management
VBA announced today its partnership with MPX to offer a solution for high-touch communications by integrating the HealthLinq® portal with VBASoftware and VBAGateway for a seamless payer experience. Integration with VBASoftware provides registrations, claims, permissions, and other data needed to support communication between members and vendors without managing file workflows. Integration […]
